{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:28:57Z","timestamp":1793651337756,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA294071"],"award-info":[{"award-number":["R01CA294071"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.hoc.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:17:18Z","timestamp":1790767038000},"page":"1023-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T Cell Therapy for Glioblastoma: Clinical Advances and Emerging Strategies"],"prefix":"10.1016","volume":"40","author":[{"given":"Eric P.","family":"Grewal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishab","family":"Ramapriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"William T.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hoc.2026.08.001_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.001_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(25)00705-3","article-title":"20 years of the Stupp protocol: confronting stagnation in glioblastoma therapy","volume":"27","author":"Khasraw","year":"2026","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.08.001_bib3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"Car t cells and t-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.001_bib4","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.001_bib5","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2018.2.FOCUS17788","article-title":"Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons","volume":"44","author":"Choi","year":"2018","journal-title":"Neurosurg Focus"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.001_bib6","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1158\/1078-0432.CCR-18-1625","article-title":"Immunotherapy for glioblastoma: adoptive t-cell strategies","volume":"25","author":"Choi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.08.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108667","article-title":"Altered cancer metabolism and implications for next-generation CAR T-cell therapies","volume":"259","author":"Ramapriyan","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib8","article-title":"Tandem chimeric antigen receptor (Car) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.001_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11060-024-04909-7","article-title":"Clinical progress in the development of CAR T cells to treat malignant glioma","volume":"171","author":"Grewal","year":"2025","journal-title":"J Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib10","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1093\/neuros\/nyab099","article-title":"Commentary: chimeric antigen receptor t-cell therapy: updates in glioblastoma treatment","volume":"89","author":"Yu","year":"2021","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.001_bib11","first-page":"1168","article-title":"Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas","volume":"60","author":"Joshi","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.hoc.2026.08.001_bib12","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of il13r\u03b12-redirected chimeric antigen receptor cd8+ t cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.hoc.2026.08.001_bib13","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor t-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.001_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"Her2-specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.001_bib15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","article-title":"EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss","volume":"20","author":"Sampson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"399","key":"10.1016\/j.hoc.2026.08.001_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2026.08.001_bib17","article-title":"First-in-human trial of epha2-redirected car t-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.08.001_bib21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2025.43.16_suppl.2018","article-title":"A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.001_bib23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.001_bib24","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.001_bib25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14712598.2011.572874","article-title":"Bispecific antibodies engage T cells for antitumor immunotherapy","volume":"11","author":"Choi","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.001_bib26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10.1016\/j.hoc.2026.08.001_bib27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular carv3-team-e t cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"591","key":"10.1016\/j.hoc.2026.08.001_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2026.08.001_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217541","article-title":"The development and potent antitumor efficacy of CD44\/CD133 dual-targeting IL7R\u03b1-armored CAR-T cells against glioblastoma","volume":"614","author":"Zhai","year":"2025","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.001_bib30","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","article-title":"Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors","volume":"69","author":"Wakimoto","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.001_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003289","article-title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","volume":"10","author":"Seyfrid","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.001_bib32","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/neuonc\/noaf195","article-title":"Targeting TGF\u03b2 docking receptor glycoprotein A repetitions predominant (Garp) via novel chimeric antigen receptor (Car)-T cell platform to treat glioblastoma","volume":"27","author":"Wu","year":"2025","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.001_bib33","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"issue":"8047","key":"10.1016\/j.hoc.2026.08.001_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"Supplement_5","key":"10.1016\/j.hoc.2026.08.001_bib35","doi-asserted-by":"crossref","first-page":"v348","DOI":"10.1093\/neuonc\/noaf201.1380","article-title":"EXTH-46. IL-15 armored glypican-3 chimeric antigen receptor T cells exhibit antitumor in vitro and in murine models of glioblastoma","volume":"27","author":"Goethe","year":"2025","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.001_bib36","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.001_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2026.08.001_bib38","series-title":"Oncohema key","article-title":"Immunobiology and immune therapy","author":"Choi","year":"2016"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.08.001_bib39","first-page":"2008","article-title":"Immunological correlates from phase I study of CARv3-TEAM-E in patients with recurrent glioblastoma (Gbm): INCIPIENT trial","volume":"43","author":"Choi","year":"2025","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.hoc.2026.08.001_bib40","series-title":"Regular and young investigator award abstracts","article-title":"269 humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma","volume":"A299,","author":"Ramakrishna","year":"2025"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:55:35Z","timestamp":1793649335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0889858826001024"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cell Therapy for Glioblastoma: Clinical Advances and Emerging Strategies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}